VYNE - Vyne Therapeutics Inc

VYNE - Vyne Therapeutics Inc

https://vynetherapeutics.com

Recent News

Powered by Alpha Vantage

VYNE Therapeutics Inc. ( VYNE ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.12

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - VYNE Therapeutics ( NASDAQ:VYNE )

Benzinga • 2 months, 1 week ago • score: 0.03

BRIDGEWATER, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- VYNE Therapeutics Inc. VYNE ( "VYNE" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today ...

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

GlobeNewswire • 2 months, 1 week ago • score: 0.01

BRIDGEWATER, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- VYNE Therapeutics Inc. ( Nasdaq: VYNE ) ( "VYNE" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet ...

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - VYNE Therapeutics ( NASDAQ:VYNE )

Benzinga • 4 months, 3 weeks ago • score: 0.28

FDA places clinical hold on VYNE's Phase 1b trial of VYN202 due to testicular toxicity seen in preclinical dog study. VYNE halts enrollment and dosing in psoriasis study; no serious adverse events reported in participants so far. Feel unsure about the market's next move?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.

52W High

$4.30

52W Low

$0.29

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.81

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.84

EV/Revenue (<3 favorable)

10.04

P/S (TTM) (<3 favorable)

16.01

P/B (<3 favorable)

0.20

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

5.38%

Institutions (25–75% balanced)

34.54%

Shares Outstanding

25,472,200

Float

23,229,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

476,000

Gross Profit (TTM)

476,000

EPS (TTM)

-0.90

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-109.30%

ROE (TTM) (>15% strong)

-0.68%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.65

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—